Investigating the role of long noncoding RNAs in acute myeloid leukemia
Official title: The role of long noncoding RNAs in acute myeloid leukemia
Funded at University of Virginia · NIH-10990156 · Data updated 2026-11-12
This study is looking at how certain RNA molecules affect the growth and treatment of acute myeloid leukemia (AML), with the goal of finding new ways to help patients, especially those whose cancer has come back.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $415,259 |
| NIH project number | 1R21CA270067-01A1 |
| Project ID | NIH-10990156 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those experiencing relapse or resistance to standard therapies.
✕Less likely to help
Patients with other types of blood cancers or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on understanding how long noncoding RNAs influence the development and treatment of acute myeloid leukemia (AML), a serious blood cancer. The team aims to identify molecular regulators that interact with cancer-associated transcription factors, which are crucial for the disease's progression and resistance to treatment. By studying these RNA molecules, the researchers hope to uncover new therapeutic strategies that could improve patient outcomes, especially for those with relapsed AML. The approach involves analyzing the effects of specific noncoding RNAs on myeloid cell differentiation and growth inhibition.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that overcome drug resistance in AML patients.
How similar studies have gone: Previous research has shown promise in targeting noncoding RNAs for cancer treatment, suggesting that this approach could yield significant advancements in AML therapy.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Trinh, Bon Q — University of Virginia
- Study coordinator: Trinh, Bon Q
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.